Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Rahul Aggarwal (ucsf)
Headshot of Rahul Aggarwal
Rahul Aggarwal

Description

Summary

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Official Title

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Details

Keywords

Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Phase 1, MOMA-313, Polymerase theta, MOMA Therapeutics, HRD Mutation, Neoplasms, Prostatic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Olaparib

Eligibility

Locations

  • Investigative Site #111 accepting new patients
    San Francisco California 94143 United States
  • Investigative Site #101 accepting new patients
    La Jolla California 92093 United States

Lead Scientist at University of California Health

  • Rahul Aggarwal (ucsf)
    I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MOMA Therapeutics
ID
NCT06545942
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 158 study participants
Last Updated